(Q24197902)

1

0 references

Katja Komossa

3

0 references

Magdolna Tardy

2

0 references

author name string

Stephan Heres

4

0 references

John M Davis

Cochrane Database of Systematic Reviews

6

0 references

publication date

16 May 2012

0 references

published in

0 references

cites work

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Discontinuation of treatment with ataractic drugs. A preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Persistence of Extra-pyramidal Disorders and Psychiatric Relapse after Withdrawal of Long-Term Phenothiazine Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of nonrelapsed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Temporal Effects of Drug and Placebo in Delaying Relapse in Schizophrenic Outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Low dose fluphenazine decanoate in maintenance treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Trial of Maintenance Therapy in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Development and Prediction of Postpsychotic Depression in Neuroleptic-Treated Schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Prophylactic effect of neuroleptics in symptom-free schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Penfluridol (R 16341) as a maintenance therapy in chronic psychotic patients: a double-blind clinical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Episodic and residual thought pathology in chronic schizophrenics: effect of neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

A double-blind clinical evaluation of penfluridol (R 16 341) as a maintenance therapy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Neuroleptic responsivity of negative and positive symptoms in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Group Therapy and Maintenance Treatment of Schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

A Double-Blind Trial of Amitriptyline/Perphenazine, Perphenazine and Placebo in Chronic Withdrawn Inert Schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

A Comparison of the Effects of Oxypertine and Trifluoperazine in Withdrawn Schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

The Northwick Park "functional" psychosis study: diagnosis and treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

A Non-neuroleptic Treatment for Schizophrenia: Analysis of the Two-year Postdischarge Risk of Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Soteria: Evaluation of a home-based treatment for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Maintenance psychotropic drugs in the presence of active treatment programs. A "triple-blind" withdrawal study with long-term mental patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

d-Amphetamine raises serum prolactin in man: Evaluations after chronic placebo, lithium and pimozide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Fluphenazine Enanthate and Fluphenazine Decanoate: A Comparison of Their Duration of Action and Motor Side Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Effectiveness of targeted intervention and maintenance pharmacotherapy in conjunction with family intervention in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

VALUE OF CONTINUOUS DRUG ADMINISTRATION FOR CHRONIC LONG-TERM MENTAL HOSPITAL PATIENTS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Use of chlorpromazine and reserpine in the treatment of emotional disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Cessation of medication for people with schizophrenia already stable on chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Overview: maintenance therapy in psychiatry: I. Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Olanzapine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Neuroleptic withdrawal in schizophrenic patients. A review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Clinical implications of Brief Psychiatric Rating Scale scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

What does the PANSS mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Schizophrenia and employment - a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Safety reporting in randomized trials of mental health interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Atypical antipsychotic drugs and the risk of sudden cardiac death

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Quetiapine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Clozapine versus typical neuroleptic medication for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Violence and schizophrenia: examining the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Influence of antipsychotics on mortality in schizophrenia: systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

Denial of illness in schizophrenic out-patients: effects of psychopharmacological treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization--a reevaluation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Long-acting phenothiazine (fluphenazine decanoate) treatment of psychosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Suicide in schizophrenics, manics, depressives, and surgical controls. A comparison with general population suicide mortality

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Fluphenazine vs Placebo in Patients With Remitted, Acute First-Episode Schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Neuroleptics and Depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Penfluridol: a long-acting oral neuroleptic. A controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Prophylactic effect of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of haloperidol and propericiazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

A depot neuroleptic withdrawal study neurological effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Language comprehension in schizophrenia: trait or state indicator?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

DISCONTINUATION OR REDUCTION OF CHEMOTHERAPY IN CHRONIC SCHIZOPHRENICS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

The clinical relevance of an auditory attention task (PAT) in a longitudinal study of chronic schizophrenia, with placebo substitution for chlorpromazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia. A two year longitudinal study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

A double-blind randomized placebo-controlled study of relapse prevention in remitted first-episode psychosis patients following one year of maintenance therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Maintenance treatment of schizophrenic outpatients with a depot phenothiazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

A self-rating scale of distress

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

1 reference

7 January 2021

Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Discontinuance of tranquilizers among chronic schizophrenic patients receiving maintenance dosage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Sudden removal of tranquilizing drugs from chronic psychiatric patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Behavioral effects of interrupting and resuming tranquilizing medication among schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Intermittent chemotherapy for chronic psychiatric inpatients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Paranoid and withdrawal symptoms in schizophrenia: differential symptom reduction over time

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Discontinuation of neuroleptic medication in older, outpatient schizophrenics. A placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

A double blind controlled trial of thiothixene and perphenazine in chronic schizophrenics shown to require maintenance therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Efficacy of maintenance use of anticholinergic agents

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Termination of chlorpromazine with schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

PHENOTHIAZINE EXCRETION IN CHRONIC SCHIZOPHRENICS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Further studies with fluphenazine enanthate: II. Relapse rate in patients deprived of medication

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

High Dose Trifluoperazine Therapy in Chronic Schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Penfluridol: An Efficacious Long-Acting Oral Antipsychotic Compound

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Pharmacokinetics and antipsychotic effect of remoxipride in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

The Northwick Park 'Functional' Psychosis Study. Phase 2: maintenance treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

WITHDRAWAL OF LONG-TERM PHENOTHIAZINES FROM CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Withdrawal of perphenazine in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Life Events and Maintenance Therapy in Schizophrenic Relapse

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Schizophrenics Fully Remitted on Neuroleptics for 3–5 years—To Stop or Continue Drugs?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Propranolol in schizophrenia. II. Clinical and biochemical aspects of combining propranolol with chlorpromazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial I. Course of illness, stability of diagnosis, and the role of a special maintenance clinic

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

A randomised controlled trial of prophylactic neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

A one year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Self-report quality of life measure for people with schizophrenia: the SQLS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008016.PUB2

7 January 2021

10.1002/14651858.CD008016.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

22592725

1 reference

Consolidated OpenCitations Corpus – April 2017